La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Blau Farmacêutica Bilan de santé

Santé financière contrôle des critères 6/6

Blau Farmacêutica possède un total de capitaux propres de R$2.0B et une dette totale de R$519.5M, ce qui porte son ratio d'endettement à 25.5%. Son actif total et son passif total sont R$3.1B et de R$1.1B. L'EBIT de Blau Farmacêutica est R$312.7M ce qui fait que son ratio de couverture des intérêts 129.4. Elle dispose de liquidités et de placements à court terme de R$376.4M.

Informations clés

25.5%

Ratio d'endettement

R$519.48m

Dette

Ratio de couverture des intérêts	129.4x
Argent liquide	R$376.38m
Fonds propres	R$2.03b
Total du passif	R$1.06b
Total des actifs	R$3.10b

Mises à jour récentes de la santé financière

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Recent updates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BLAU3 ( R$1.5B ) dépassent ses passifs à court terme ( R$376.3M ).

Passif à long terme: Les actifs à court terme de BLAU3 ( R$1.5B ) dépassent ses passifs à long terme ( R$687.8M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de BLAU3 ( 7% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de BLAU3 a été réduit de 79.2% à 25.5% au cours des 5 dernières années.

Couverture de la dette: La dette de BLAU3 est bien couverte par le flux de trésorerie opérationnel ( 45.7% ).

Couverture des intérêts: Les paiements d'intérêts de BLAU3 sur sa dette sont bien couverts par l'EBIT ( 129.4 x couverture).

Blau Farmacêutica Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Recent updates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 15%

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.29 in 1Q 2023)

Price target decreased by 9.1% to R$14.29

Upcoming dividend of R$0.014 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 14% to R$15.71

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 14%

Blau Farmacêutica S.A. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Blau Farmacêutica S.A. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.4% to R$27.39

Price target decreased by 7.1% to R$29.17

Price target decreased by 7.4% to R$31.40

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 19%

First quarter 2023 earnings released: EPS: R$0.29 (vs R$0.34 in 1Q 2022)

Price target decreased by 7.7% to R$33.91

Price target decreased by 8.3% to R$34.58

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of R$0.052 per share at 3.0% yield

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Insufficient new directors

Third quarter 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued

Now 22% undervalued

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to R$37.57

Now 21% undervalued after recent price drop

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Second quarter 2021 earnings released: EPS R$0.56 (vs R$0.50 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS R$0.58 (vs R$0.21 in 1Q 2020)

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines